Moderna, COVID
Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster COVID-19 vaccines of infringing one of its patents.
Moderna has suffered its second PMCPA rebuke in quick succession. Days after ruling Moderna had brought discredit on the ...
We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Moderna, ...
Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor Pharma ...
The PCMPA has slammed Moderna over an unapproved WhatsApp message that offered children 1,500 pounds sterling ($2,000) to ...
Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, ...
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
CAMBRIDGE, MA and TAIPEI, TAIWAN / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare, the sales and marketing ...
Moderna (MRNA) closed at $66.83 in the latest trading session, marking a +1.64% move from the prior day. This change outpaced the S&P 500's 0.42% gain on the day. Meanwhile, the Dow experienced a rise ...